13F Pro13F Pro

SILVERARC CAPITAL MANAGEMENT, LLC

Institutional InvestorSimilar funds →SEC EDGAR: CIK 1816307
Institutional-grade research for retail investors

Sector Allocation

  • Healthcare98.2%$882.1M
  • Other1.4%$12.5M
  • Financials0.4%$3.9M

AUM History

13fpro.ai/research/fund/silverarc-capital-management-llc-1816307

Conviction and streaks

Diversifying · top 10 = 45.3%

From the fund's last 12 quarters of 13F filings: positions held longest at size, and names it added to or trimmed several quarters running.

CELC$CELCConviction hold5.8% weight · held 4 quartersCOGT$COGTConviction hold5.5% weight · held 4 quartersURGN$URGNConviction hold5.3% weight · held 10 quartersDNTH$DNTHConviction hold4.2% weight · held 6 quartersRYTM$RYTMConviction hold3.9% weight · held 10 quartersCERS$CERSAccumulating+137% shares · 8 quarters runningSNDX$SNDXAccumulating+201% shares · 4 quarters runningIMNM$IMNMAccumulating+26833% shares · 3 quarters runningRYTM$RYTMAccumulating+129% shares · 2 quarters runningELVN$ELVNAccumulating+4794% shares · 2 quarters runningINSM$INSMTrimming-91% shares · 6 quarters runningABVX$ABVXTrimming-69% shares · 3 quarters runningBIIB$BIIBTrimming-40% shares · 3 quarters runningORIC$ORICTrimming-62% shares · 3 quarters runningELUT$ELUTTrimming-23% shares · 3 quarters running

Largest positions — Q2 2026

Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.

13fpro.ai/research/fund/silverarc-capital-management-llc-1816307

SILVERARC CAPITAL MANAGEMENT, LLC 13F holdings — Q2 2026

$962.2M portfolio (-1.8% QoQ) · 73 holdings · Q2 2026 13F · top 10 are 45% of the stock portfolio

Includes $63.6M of put/call options ($25.7M puts, $37.9M calls), which 13F rules report at the value of the underlying shares, not the premium at risk. Stocks alone: $898.5M. Weights use the stock portfolio.

All holdings — SILVERARC CAPITAL MANAGEMENT, LLC (Q2 2026)

73 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.

Company
ELVN$ELVNEnliven Therapeutics, Inc.$24.8MNew
IMVT$IMVTImmunovant, Inc.$23.9M+49%
ERAS$ERASErasca, Inc.$23.1M-32%
SGMT$SGMTSagimet Biosciences Inc.$22.6MNew
ABVX$ABVXAbivax S.A.adr$22.6M-44%
PRAX$PRAXPraxis Precision Medicines, Inc.$22.0M-8%
KOD$KODKodiak Sciences Inc.$21.3M-45%
— PUTARK ETF TR - PUT$21.0MNew
DFTX$DFTXDefinium Therapeutics, Inc.$18.8MNew
VCYT$VCYTVERACYTE, INC.$18.7M+77%
SNDX$SNDXCALLSyndax Pharmaceuticals Inc$15.2M+117%
GH$GHGuardant Health, Inc.$15.0M+1%
CCCC$CCCCC4 Therapeutics, Inc.$14.2M+59%
ZBIO$ZBIOZenas BioPharma, Inc.$12.9M-55%
TRVI$TRVITrevi Therapeutics, Inc.$12.6M+33%

What changed in Q2 2026

Against the previous quarter's 13F: 25 new, 18 added to, 27 trimmed, 25 sold out. Share-count changes; largest moves by dollar size first.

New positions (25)

  • ELVN$ELVNEnliven Therapeutics, Inc.$24.8M

    first bought this quarter

  • SGMT$SGMTSagimet Biosciences Inc.$22.6M

    first bought this quarter

  • PUTARK ETF TR - PUT$21.0M

    first bought this quarter

  • DFTX$DFTXDefinium Therapeutics, Inc.$18.8M

    first bought this quarter

  • ALXO$ALXOALX ONCOLOGY HOLDINGS INC$11.9M

    first bought this quarter

  • MANE$MANEVeradermics, Inc$11.7M

    first bought this quarter

+19 more in the Excel export

Added to (18)

  • ASND$ASNDAscendis Pharma A/S+65%

    now $55.0M · held 8 qtrs, 2 adds in a row

  • ORKA$ORKAOruka Therapeutics, Inc.+134%

    now $33.6M · held 2 qtrs, 2 adds in a row

  • CELC$CELCCelcuity Inc.+40%

    now $52.4M · held 4 qtrs

  • SNDX$SNDXCALLSyndax Pharmaceuticals Inc+117%

    now $15.2M

  • VCYT$VCYTVERACYTE, INC.+77%

    now $18.7M · held 10+ qtrs

  • IMVT$IMVTImmunovant, Inc.+49%

    now $23.9M · held 2 qtrs, 2 adds in a row

+12 more in the Excel export

Trimmed (27)

  • DNTH$DNTHDianthus Therapeutics, Inc. /DE/-40%

    now $38.0M · held 6 qtrs, 2 trims in a row

  • GLUE$GLUEMonte Rosa Therapeutics, Inc.-45%

    now $26.8M · held 4 qtrs

  • ALKS$ALKSAlkermes plc.-75%

    now $5.9M · held 2 qtrs

  • ABVX$ABVXAbivax S.A.-44%

    now $22.6M · held 4 qtrs, 3 trims in a row

  • KOD$KODKodiak Sciences Inc.-45%

    now $21.3M · held 10+ qtrs, 2 trims in a row

  • ZBIO$ZBIOZenas BioPharma, Inc.-55%

    now $12.9M · held 2 qtrs

+21 more in the Excel export

Sold out (25)

  • PUTSPDR SERIES TRUSTwas $105.4M
  • KALV$KALVKalVista Pharmaceuticals, Inc.was $57.9M

    held 9+ qtrs

  • NUVL$NUVLNuvalent, Inc.was $36.4M

    held 9+ qtrs

  • CNTA$CNTACentessa Pharmaceuticals plcwas $18.5M

    held 7 qtrs

  • SRRK$SRRKScholar Rock Holding Corpwas $16.7M

    held 1 qtr

  • CGON$CGONCG Oncology, Inc.was $11.3M

+19 more in the Excel export

Firm AUM (Form ADV): $1.6B as of 2025-12-31 · SEC IAPD

Share

Holdings by quarter

Every 13F SILVERARC CAPITAL MANAGEMENT, LLC has filed, 22 earlier quarters. Pick one to see what it held then.

Email me the moment this fund files its next 13FPro

Is it too late to follow SILVERARC CAPITAL MANAGEMENT?

Q2 2026 13F filed with the SEC on Aug 13, 2026. Prices are closing prices as of Oct 26, 2026.

Average quality of SILVERARC CAPITAL MANAGEMENT's top 20 holdings: 37/100 (our AI quality score, weighted by position size; 8 of the 20 are scored)

Top 10 since filing

-22.2%

Value-weighted move of the 10 largest stock positions

Turnover

30%

Last quarter; 114% over the last 4

Top 10 weight

45%

Share of the stock portfolio in its 10 largest positions

Held 4+ quarters

61%

Share of portfolio value in positions held a year or more

Highest-quality names it owns(among its 100 largest positions)

The 8 highest-scoring companies in this portfolio are a Pro feature.

How these are measured
  • Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
  • Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
  • Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q1 2024 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
  • Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
  • Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.

Portfolio Overview

SILVERARC CAPITAL MANAGEMENT, LLC disclosed 73 positions worth $962.2M in its Form 13F-HR for Q2 2026 — $898.5M in common stock plus $63.6M of put/call option positions (reported at underlying notional value, not premium at risk), led by $ASND (Ascendis Pharma A/S) at 6.1% of the equity portfolio, followed by $CELC and $COGT. During the quarter the fund opened 25 new positions and exited 25 — including a new stake in $ELVN. The portfolio is most concentrated in Healthcare (98.2% of disclosed assets). All figures are sourced directly from SILVERARC CAPITAL MANAGEMENT, LLC’s Form 13F-HR filing with the SEC under CIK 1816307.

Funds like this

managers whose biggest positions overlap SILVERARC CAPITAL MANAGEMENT's
TCG Crossover Management, LLC$4.16B 13F book · 8 shared top holdingsCOGTDNTHABVXIMVTFirst Turn Management, LLC$934.72M 13F book · 12 shared top holdingsCELCABVXDNTHELVNPERCEPTIVE ADVISORS LLC$6.66B 13F book · 8 shared top holdingsCELCRYTMPRAXORKABAKER BROS. ADVISORS LP$19.96B 13F book · 8 shared top holdingsCELCRYTMPRAXKODLogos Global Management LP$2.32B 13F book · 12 shared top holdingsDNTHABVXERASPRAXAffinity Asset Advisors, LLC$2.21B 13F book · 13 shared top holdingsORKAERASPRAXABVX

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock

to search all 8,700+ institutional filers.

AI-Powered Hedge Fund Analysis: SILVERARC CAPITAL MANAGEMENT, LLC

13F Pro is an AI hedge fund tracker and stock research platform. For SILVERARC CAPITAL MANAGEMENT, LLC (SEC CIK: 1816307), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in SILVERARC CAPITAL MANAGEMENT, LLC's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.